Several molecular alterations have been proposed to support tumor resistance to cytotoxic drugs, such as the expression of MDR phenotype, mutation of p53, bcl2 overexpression [3-5], but only very recently it has been recognized that specific molecular or biological profiles might characterize tumor sensitivity to classes of agents with different mechanisms of action. This evidence concerns the gene BCL2 and neoplasm.